Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly LLY -1.05% ...

LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Investing.com -- The American College of Cardiology released new recommendations on Friday stating that millions more ...

A radical shifting of trade flows has given Ireland the second-biggest trade imbalance with the U.S. after China, mostly due to demand for weight-loss drugs.

GLP-1 drugs such as Wegovy and Zepbound are growing increasingly prominent. But some food ingredients can also cause the body ...

Millions more Americans should be taking weight-loss drugs to prevent heart disease, according to the American College of ...

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

It has been found in a phase I study that patients taking Eli Lilly's investigational obesity drug eloralintide lost more ...

Shares of weight-loss drugmakers Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) spiked after the American College of Cardiology ...

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with the U.S., trailing only China.